Hologic CEO Steve MacMillan to be Joined by Susan G. Komen Founder Nancy Brinker and Pink Hope Founder Krystal Barter to Ring Nasdaq Opening Bell on October 1

Hologic, Inc. (Nasdaq: HOLX) announced today that Nancy G. Brinker, global cancer advocate, Hologic consultant and founder of Susan G. Komen, and Krystal Barter, author and founder of Australian nonprofit Pink Hope, will join Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, and selected employees to ring the Nasdaq Opening Bell for the 13^th consecutive year on October 1 to mark the start of Breast Cancer Awareness Month.

In addition to appearing at the Nasdaq MarketSite, Hologic will recognize Breast Cancer Awareness Month by announcing the results from their recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the effect it has on breast cancer screening and cancer detection. Most notably, the survey found 64 percent of U.S. women do not know that the density of a woman’s breasts affects her risk of developing breast cancer; more than two-thirds of U.S. women (68%) do not know their breast density score; and just 36 percent of women have discussed their breast density with a medical professional.¹ Grammy award-winning artist, breast cancer survivor and Genius exam spokesperson Sheryl Crow will educate women on this important topic throughout the month via traditional, digital and social media.

Hologic is the pioneer behind the Genius 3D Mammography exam, the first breast tomosynthesis exam approved by the FDA in 2011. The Genius exam detects 20-65 percent more invasive breast cancers and is the only mammogram approved by the FDA as superior for women with dense breasts compared to 2D alone.^2,3 Nearly half of women between the ages of 40 to 74 have dense breasts, which can make it difficult to detect breast cancer during annual screenings.^4,5 Density is only identifiable on a mammogram or other imaging modalities, and reflects how much fibrous or glandular tissue is in the breast. Women with dense breasts often require additional imaging, which can result in increased patient anxiety and unnecessary costs. Perhaps most important, women with very dense breasts are four to five times more likely to develop breast cancer than women with less dense breasts.^6,7